5-alpha reductase inhibitor

(redirected from 5-alpha-reductase inhibitor)
Also found in: Wikipedia.

5-alpha reductase inhibitor

A medication to treat benign prostatic hyperplasia. It blocks the conversion of testosterone to dihydrotestosterone.
See also: inhibitor
References in periodicals archive ?
The decrease in PSA in the Se-SM group shows that prophylaxis due to the Se-SM combination may be as effective as 5-alpha-reductase inhibitor treatment (Tindall and Rittmaster, 2008).
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5-alpha-reductase inhibitor dutasteride.
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
At the time of presentation, his medications included a 5-alpha-reductase inhibitor (dutasteride) and his anti-Parkinsonian medications (levodopa and the dopamine agonist pramipexole).
Approximately half were randomly assigned to take the 5-alpha-reductase inhibitor finasteride and half to take placebo for 7 years.
The Prostate Cancer Prevention Trial prospectively evaluated finasteride, a 5-alpha-reductase inhibitor, as chemoprevention.
But if a man is taking either Proscar or Propecia or another 5-alpha-reductase inhibitor, the lab report will show it.
Many of us will reach for an alpha-adrenergic antagonist or a 5-alpha-reductase inhibitor as first-line therapy for patients with mild but annoying symptoms.
Dutasteride and finasteride, another 5-alpha-reductase inhibitor, were shot down as prostate chemoprevention agents in December 2010 by the FDA's Oncologic Drugs Advisory Committee on the basis that the risk-benefit profile for either drug is not favorable when it is used to reduce the risk of prostate cancer.
5-alpha-reductase inhibitors (5-ARIs) are a totally different kind of drug, which shrink the glandular tissue of the prostate, reducing its bulk to eventually reduce constriction by the prostate as well.
4] The mainstay of medical treatments includes alpha-blockers, 5-alpha-reductase inhibitors (5-ARIs), or a combination of the two.
First-line therapies indude alpha-1 adrenergic receptor antagonists (alpha-blockers) and 5-alpha-reductase inhibitors (5-AR1s).

Full browser ?